论文信息 - Activation of MET pathway predicts poor outcome to cetuximab in patients with recurrent or metastatic head and neck cancer - 字舞流文

Activation of MET pathway predicts poor outcome to cetuximab in patients with recurrent or metastatic head and neck cancer

F. Rojo | J. Madoz-Gúrpide | S. Zazo | C. Chamizo | J. García-Foncillas | C. Caramés | I. Cristóbal | V. Casado | E. Gavín